{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-013437","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.390048+00:00","generated_at":"2026-06-25T21:42:27.607983+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aurinia Q1 net revenue $21.6M, net loss $37.6M; FY22 guidance reaffirmed","bullets":["Net product revenue $21.6M (Q1 2021: $0.9M); net loss $37.6M ($0.27/shr) vs $50.4M ($0.40) YoY.","Maintains FY2022 LUPKYNIS revenue guidance $115-$135M, representing 150-200% growth over FY2021.","Patients on LUPKYNIS reached ~1,071 at March 31, 2022, up 21% from 884 at December 31, 2021.","EMA review on track; European Commission decision expected in second half of 2022.","Cash, cash equivalents and investments $418.8M at March 31, 2022, down from $466.1M at year-end 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-013437","json":"https://secwatch.observer/filing/0001628280-22-013437.json","markdown":"https://secwatch.observer/filing/0001628280-22-013437.md","text":"https://secwatch.observer/filing/0001628280-22-013437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022013437/0001628280-22-013437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022013437/auph-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:42:27.607983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}